LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

REVOLUTION Medicines Inc

Gesloten

SectorGezondheidszorg

38 2.26

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

37.21

Max

38.23

Belangrijke statistieken

By Trading Economics

Inkomsten

-34M

-248M

EPS

-1.13

Winstmarge

-74.379

Werknemers

700

EBITDA

-24M

-261M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+85.52% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-258M

6.7B

Vorige openingsprijs

35.74

Vorige sluitingsprijs

38

Nieuwssentiment

By Acuity

34%

66%

88 / 372 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 aug 2025, 22:51 UTC

Winsten

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Rev $4.01B

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H Adj EPS $1.84

27 aug 2025, 23:57 UTC

Winsten

Trip.com Group 1H EPS $1.82

27 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug 2025, 23:39 UTC

Winsten

Correction to Nvidia Earnings Article -- WSJ

27 aug 2025, 22:59 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 aug 2025, 22:59 UTC

Marktinformatie

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug 2025, 22:58 UTC

Winsten

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug 2025, 22:57 UTC

Winsten

South32 FY Free Cash Flow $192 Million

27 aug 2025, 22:56 UTC

Winsten

South32 FY Total Capital Expenditure $1.35 Billion

27 aug 2025, 22:56 UTC

Winsten

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug 2025, 22:55 UTC

Winsten

South32 Net Cash $123 Million at June 30

27 aug 2025, 22:54 UTC

Winsten

South32: Focused on Maintaining Strong Operating Momentum

27 aug 2025, 22:53 UTC

Winsten

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug 2025, 22:53 UTC

Winsten

South32 Extends Capital Management Program for 12 Months

27 aug 2025, 22:52 UTC

Winsten

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug 2025, 22:51 UTC

Winsten

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug 2025, 22:50 UTC

Winsten

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug 2025, 22:50 UTC

Winsten

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug 2025, 22:45 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug 2025, 22:44 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug 2025, 22:43 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug 2025, 22:43 UTC

Winsten

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug 2025, 22:42 UTC

Winsten

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources Net Debt $123 Million at June 30

27 aug 2025, 22:40 UTC

Winsten

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

85.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 69.16 USD  85.52%

Hoogste 80 USD

Laagste 37.91 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

88 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.